Pancreatic cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

While pancreatic cancer has an inherited or rapidly acquired chemoresistance, a meta-analysis of data from published clinical trials reported a significant improvement in overall survival (OS) among patients receiving chemotherapy [1]. Nowadays, gemcitabine is widely accepted as the standard first-line therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.

Original languageEnglish
Title of host publicationImaging Tumor Response to Therapy
PublisherSpringer-Verlag Italia s.r.l.
Pages127-140
Number of pages14
ISBN (Print)9788847026131, 9788847026124
DOIs
Publication statusPublished - Jan 1 2012

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Orsi, M., Losio, C., Reni, M., Muzio, N. D., De Cobelli, F., & Maschio, A. D. (2012). Pancreatic cancer. In Imaging Tumor Response to Therapy (pp. 127-140). Springer-Verlag Italia s.r.l.. https://doi.org/10.1007/978-88-470-2613-1_8